Search

Your search keyword '"Korolenko VO"' showing total 2 results
Start Over Author "Korolenko VO" Topic antineoplastic combined chemotherapy protocols
2 results on '"Korolenko VO"'

1. [Complications of chemotherapy in combination with bevacizumab for treating metastatic colorectal cancer].

Author

Manikhas GM, Korolenko VO, Al'-Nekhmi AA, and Antimonik NIu

Subjects
Aged, Angiogenesis Inhibitors administration & dosage, Antibodies, Monoclonal administration & dosage, Antibodies, Monoclonal, Humanized, Bevacizumab, Colorectal Neoplasms pathology, Female, Hematologic Diseases chemically induced, Humans, Male, Middle Aged, Muscle Weakness chemically induced, Nausea chemically induced, Neoplasm Staging, Quality of Life, Stomatitis chemically induced, Treatment Outcome, Vomiting chemically induced, Angiogenesis Inhibitors adverse effects, Antibodies, Monoclonal adverse effects, Antineoplastic Combined Chemotherapy Protocols adverse effects, Colorectal Neoplasms drug therapy
Abstract

Ninety-six patients with unresectable or metastatic colorectal cancer received first-line chemotherapy plus bevacizumab. The purpose of our study was to evaluate the safety and efficacy of the therapy. Median relapse-free survival lasted 10.4 months. Addition of bevacizumab was well tolerated and may be recommended for clinical use.

Published
2010

2. [Stimulating and protective effect of recombinant interleukin-1-beta (beta-leukin) on leukopoiesis in chemotherapy of malignant tumors].

Author

Gershanovich ML, Ketlinskiĭ SA, Filatova LV, Danova LA, Korolenko VO, and Simbirtsev AS

Subjects
Adolescent, Adult, Female, Hematopoiesis drug effects, Humans, Interleukin-1 pharmacology, Leukopenia chemically induced, Male, Middle Aged, Recombinant Proteins pharmacology, Recombinant Proteins therapeutic use, Treatment Outcome, Antineoplastic Combined Chemotherapy Protocols administration & dosage, Antineoplastic Combined Chemotherapy Protocols adverse effects, Granulocytes drug effects, Interleukin-1 therapeutic use, Leukopenia drug therapy, Leukopenia prevention & control, Lymphocytes drug effects, Sarcoma drug therapy
Abstract

Clinical studies were carried out in a group of 71 cancer patients to evaluate the effects of intravenous infusion of human recombinant interleukin-1-beta (betaleukin) (I and II phases). It was shown that daily single doses of 10-20 ng/kg body, for 5 days, markedly stimulated leukopoiesis (granulocytopoiesis) in toxic (grade II-IV) leukopenia which hampered combination chemotherapy. A protective effect on leukopoiesis (granulocy-topoiesis) was recorded in cases of moderate leukopenia when chemotherapy was continued. Such side-effects as stage I-III hyperthermia (13.5%) or their combination (50.0%) were effectively managed with paracetamol and antihistamines administration without causing suspension of the drug.

Published
1996

Catalog

Books, media, physical & digital resources
See catalog results